Ivy Brain Tumor Center Welcomes Biostatistician to Phase 0 Clinical Trials Program
29 sept. 2020 08h00 HE
|
Ivy Brain Tumor Center
PHOENIX, Ariz., Sept. 29, 2020 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute is pleased to announce the addition of Wonsuk Yoo, PhD, as associate professor of...
CNS Pharmaceuticals and Image Analysis Group Partner to Further the Development of Berubicin
24 sept. 2020 08h00 HE
|
CNS Pharmaceuticals, Inc.
HOUSTON, Sept. 24, 2020 (GLOBE NEWSWIRE) -- via NetworkWire -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel...
IN8bio Names Kate Rochlin, PhD Assistant Vice President Operations and Innovation
17 sept. 2020 07h00 HE
|
IN8bio, Inc.
NEW YORK, Sept. 17, 2020 (GLOBE NEWSWIRE) -- IN8bio, Inc., a clinical-stage biotechnology company focused on developing innovative therapies for the treatment of cancers, including solid tumors, by...
Incysus Therapeutics Announces Name Change to IN8bio, Inc.
24 août 2020 07h00 HE
|
IN8bio, Inc.
NEW YORK, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on delivering innovative gamma-delta (γδ) T cell immunotherapies for the...
Incysus Therapeutics to Present at Solebury Trout Private Company Showcase
07 août 2020 08h35 HE
|
Incysus Therapeutics, Inc.
NEW YORK, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a clinical-stage biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell...
Incysus Therapeutics to Present at LifeSci Partners Summer Symposium
03 août 2020 07h00 HE
|
Incysus Therapeutics, Inc.
NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a clinical-stage biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell...
First Patient Treated in Phase 1 Clinical Trial Of Incysus Therapeutics Gamma Delta (γδ) T Cell Immunotherapy for Patients With Newly Diagnosed Glioblastoma
02 juin 2020 07h00 HE
|
Incysus Therapeutics, Inc.
NEW YORK, June 02, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
Incysus Therapeutics Announces Poster Presentation at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting
28 mai 2020 07h00 HE
|
Incysus Therapeutics, Inc.
NEW YORK, May 28, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...
INCYSUS THERAPEUTICS TO PRESENT AT THE 2020 SOLEBURY TROUT VIRTUAL INVESTOR CONFERENCE
06 avr. 2020 07h00 HE
|
Incysus Therapeutics, Inc.
NEW YORK, April 06, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a clinical-stage biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell...
Incysus Therapeutics Initiates Enrollment in Phase 1 Study of a Genetically Modified Gamma-Delta (γδ) T Cell Immunotherapy in Patients with Newly Diagnosed Glioblastoma
27 févr. 2020 07h00 HE
|
Incysus Therapeutics, Inc.
NEW YORK, Feb. 27, 2020 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the...